Stock News

AstraZeneca Beats Estimates Aided by Cancer Drugs

COVID-vaccine maker AstraZeneca beats the $10.73 billion consensus estimates with its $10.98 billion total revenue for Q3, aided by the sales of its cancer drugs.

AstraZeneca, whose most extensive disease area is oncology, accounted for close to 63% of total sales for its cancer drugs last year. The sales of the pharmaceutical company’s oncology portfolio also rose by 24%, with earnings from key cancer medicines Tagrisso and Imfinzi helping them beat the consensus estimates.

Sales generated by Tagrisso were near $1.4 billion and Imfinzi at $737 million, while analysts’ forecast was only at $1.35 billion and $725 million, respectively.

According to an analyst, “Whilst some of the other key players in the COVID-19 market started to show a decline in momentum, AstraZeneca’s diversified portfolio…has allowed them to stay on top and not be affected by the reduced global uptake of vaccines.”

AstraZeneca raised its core earnings outlook for the entire business year, expecting a metric increase by a high-20s to low-30s percentage compared to its prior outlook of mid-to-high 20s percentage.

 

Related Post

AstraZeneca’s Adult Asthma Drug Backed by FDA Adcomm

The Pulmonary-Allergy Drugs Advisory Committee of FDA favored AstraZeneca’s PT027 (albuterol/budesonide) on Wednesday, saying that the drug has promising risk-benefits for asthma patients 18 and above but not as much for younger ones.

PADAC decided in a 9 to 8 vote that the drug doesn’t have an overall positive risk-benefit for asthma patients in ages 12 to 17 years old. The vote was even worse for 4 to 11 years old children as the committee voted 16-1 against PT027.

Former President of the American College of Allergy, Asthma, and Immunology, Bradley E. Chipps, noted that the current asthma rescue medications do not address the “underlying inflammation” but only alleviate the exacerbation symptoms.

With PADAC’s vote, PT027 has become the only rescue medication to receive a recommendation for approval in the US.

“If approved, PT027 could transform the current rescue treatment approach,” Chipps added.

User Review
0 (0 votes)

Recent Posts

  • Commodity News

Oil Mixed as Traders Anticipate the US to Replenish Its SPR

On Thursday, oil prices were mixed amid speculation that the US would soon restock its…

3 days ago
  • Technology News

Microsoft Signs Deal to Power AI Ambitions with Renewables

Microsoft has inked a renewable energy deal with Brookfield Asset Management with hopes of powering…

3 days ago
  • Stock News

Asian Stocks Gain on Tech Surge Ahead of US Nonfarm Payrolls

Asian stocks traded higher on Friday, with the tech sector taking the lead following better-than-expected…

3 days ago
  • Technology News

Tesla Withdraws Next-Gen Gigacasting Manufacturing Process

Tesla has reportedly retreated from its ambitious plan for innovations in gigacasting its developing manufacturing…

4 days ago
  • Broker News

Dukascopy Sees Dip in 2023 Profits, Netting CHF 1.3 Million

Dukascopy Bank SA noted a net profit of CHF 1.3 million last year amidst market…

4 days ago
  • Commodity News

Cocoa Crashes as Traders Delay Purchases from West Africa

On Wednesday, cocoa prices plunged after a liquidity crunch forced traders and speculators to postpone…

4 days ago

This website uses cookies.